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Background: The EUBIROD project aims to perform a cross-border flow of diabetes information across 19
European countries using the BIRO information system, which embeds privacy principles and data protection
mechanisms in its architecture (privacy by design). A specific task of EUBIROD was to investigate the variability in
the implementation of the EU Data Protection Directive (DPD) across participating centres. Methods: Compliance
with privacy requirements was assessed by means of a specific questionnaire administered to all participating
diabetes registers. Items included relevant issues e.g. patient consent, accountability of data custodian, commu-
nication (openness) and complaint procedures (challenging compliance), authority to disclose, accuracy, access
and use of personal information, and anonymization. The identification of an ad hoc scoring system and stat-
istical software allowed an overall quali-quantitative analysis and independent evaluation of questionnaire
responses, automated through a dedicated IT platform (‘privacy performance assessment’). Results: A total of
18 diabetes registers from different countries completed the survey. Over 50% of the registers recorded a
maximum score for accountability, openness, anonymization and challenging compliance. Low average values
were found for disclosure and disposition, access, consent, use of personal information and accuracy. A high
heterogeneity was found for anonymization, consent, accuracy and access. Conclusions: The novel method of
privacy performance assessment realized in EUBIROD may improve the respect of privacy in each data source,
reduce overall variability in the implementation of privacy principles and favour a sound and legitimate
cross-border exchange of high quality data across Europe.
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
Introduction
Healthcare information systems offer crucial advantages forimproving public health. The integrated availability of health
data promotes optimization of health systems, efficiency savings,
increased safety and health benefits.1
Although the European Union has taken steps to improve the
availability of quality data across Europe, health information is
still not homogeneous and often not efficiently used for policy
making.2 A major obstacle to the use of data for international
comparisons is the lack of harmonization of international
privacy policies, which has sometimes posed unnecessary legisla-
tive constraints on the processing of data for public health
purposes.
Health information systems, which strongly rely on advanced IT
solutions, pose technical challenges to existing privacy/data
protection legal frameworks.3 Opportunity and risks arise from the
increased hardware capacity (storage, processing speed), more
powerful software (data management systems and data mining)
and the easier interconnection and interoperability across different
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systems, which facilitates the secondary use of health data and data
linkage.
However, legislative barriers to the implementation of efficient
health information systems can be overcome by adopting appropri-
ate safeguards and privacy protective solutions. Targeted legislative
instruments are needed to reconcile the conflicting interests of the
right to privacy/data protection with those of the right to health/
health care.
The right to privacy, recognized in many international treaties,4–7
became legally binding for Member States (MS) with the entry into
force of the Lisbon Treaty in 2009, which incorporated the Charter
of Fundamental Rights of the European Union.8 While Article 7 of
the Charter recognizes the fundamental human right to privacy,
Article 8 specifically protect personal data as an autonomous
human right, different from, but closely linked to the right to
privacy. Furthermore, the Lisbon Treaty introduced a new legal
basis to establish a comprehensive and coherent Union legislation
through Article 16 of the Treaty on the Functioning of the European
Union.9
On this basis, the Commission is undergoing a revision of the EU
Data Protection Directive (DPD).10 Accordingly, a ‘Communication
on a comprehensive approach on personal data protection in the
European Union’11 has been enacted in 2010 to address the new
technological challenges for data protection and to overcome
pitfalls in the implementation of the DPD across MS. The
Communication acknowledges that privacy and data protection
rights should not unnecessarily limit other fundamental rights
enshrined in EU Treaties, including the right to health/health care.
It also highlights that, despite of a common EU legal framework,
there is a lack of harmonization among the legislation of MS on
different aspects of data protection, including data processing for
public health purposes. The divergent implementation of the DPD
across MS may produce both an inadequate protection of the right
to privacy/data protection and unnecessary legal constraints. In the
health-care sector, the direct impact of these practices produced a
substantially lower capacity of conducting effective research in
specific MS.12
The new DPD is expected to be enacted in 2012. Among the
means to promote harmonization, it will foster the use of privacy
enhancing technologies (PETs), privacy by design and privacy
impact assessment (PIA) in specific cases and particularly when
sensitive data is to be processed.11 Privacy by design and PIA are
systems engineering methodologies embedding privacy/data
protection throughout the entire life cycle of technologies.13
The BIRO14 project built a transnational ‘Shared Evidence-Based
Diabetes Information System’ to automatically deliver quality
indicators for international comparisons on a regular basis. The
project defined a European common dataset and a template for
routine reporting, realized through the development of an ad hoc
database/statistical software. In line with the Commission
Communication, the system architecture was identified through a
novel method of PIA,15 which ensured complete privacy protection
without hampering the information content for public health. The
resulting technology operates on top of distributed databases and the
transmission of aggregate data to a central server, which delivers EU
indicators.
The EUBIROD project16 implemented the BIRO technology in 19
countries to automatically produce a European Diabetes Report
including 81 quality and outcomes indicators. Sections of the report
include: demographics, clinical characteristics and risk factors, health
system structures and processes, population (prevalence rates),
risk-adjusted intermediate and terminal outcomes and paediatrics.
A novel method of ‘Privacy Performance Assessment’ (PPA) was
conceived to respond to the following questions:
 how heterogeneous is the implementation of privacy require-
ments/principles among participating centres?
 which are the key areas of concern requiring advice and
guidance? and
 how can the consistency of registers with privacy requirements be
improved?
In this article we explain how PPA can be used as a practical
solution that can help respond to the new privacy challenges in
the design of transnational health information systems.
Methods
Privacy performance assessment
The PIA method originally developed in the BIRO project focused
on the system as a whole.15 The EUBIROD PPA explored privacy
issues at the level of systems’ users, assessing the variability of data
processing procedures in 19 countries and their deviation from
EU privacy standards. Summary measures of privacy performance
were automatically provided back to users for an independent
evaluation of local policies. The PPA methodology involved the
following steps:
 identification and definition of key elements of data protection
(privacy factors) in the management of diabetes registers;
 adoption of a targeted tool (questionnaire) to collect data on
procedures used across the Consortium;
 analysis of privacy factors and variability of approaches at the
European level and
 creation of a dedicated tool to improve the management of
privacy issues.
The questionnaire adopted in EUBIROD was a revised/updated
version of the one included in the Canadian PIA Guidelines.17 Key
elements of data protection (factors) were selected to ascertain the
compliance/non-compliance with privacy principles/norms of data
processing operations occurring in EUBIROD registers.
The following eleven privacy factors were included as separate
sections in the questionnaire:
 ‘accountability of personal information’: for example, questions
on the custody and control of personal information and third
parties involvement;
 ‘collection of personal information’: on the authority to collect,
the necessity of the information collected (minimality principle),
the use of information for secondary purposes, and the provision
of anonymization for planning, management and/or evaluation
purposes;
 ‘consent’: on the necessity to gather informed consent for the
collection and processing of data in the registry, if it is obtained
from the individual, if it is clear/unambiguous and if the capacity
to give consent has been taken into account;
 ‘use of personal information’: on the authority to use infor-
mation, if the use is in compliance with the purpose speci-
fication principle and if personal identifiers are used for data
linkage;
 ‘disclosure and disposition of personal information’: on the
consent/authority to disclose personal information and/or
personal identifiers;
 ‘accuracy of personal information’: on the possibility for individ-
uals to access, assess, discuss or dispute the accuracy of his/her
record;
 ‘safeguarding personal information’: on security measures and
processes;
 ‘openness’: on the provision of communication processes and the
way personal information is managed/protected;
 ‘individual access to personal information’: evaluating the
practical implementation of access rights;
 ‘challenging compliance’: on the availability of complaint
procedures and mechanisms to ensure accountability and
 ‘anonymization process for secondary uses of health data’:
analysing the compliance with international technical standards
and principles.
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The EUBIROD PPA questionnaire, including a total of 57
questions, is available as an official project deliverable.18
Study population
The target population of the EUBIROD PPA included 19
participating diabetes registers: Healthgate Styria (Austria), IPH
Survey Belgium, Diabetes Register of Croatia, Larnaca (Cyprus),
Hillerod (Denmark), Rheinland-Pfalz (Germany), GPMSSP
Hungary, Tallaght (Ireland), Umbria (Italy), Administrative Data
Luxembourg, Mater Dei (Malta), West Friesland (the
Netherlands), Diabetes Register of Norway, Silesia (Poland),
Bucharest (Romania), DARTS Tayside (Scotland), Type 1
Childhood Diabetes Register of Slovenia, Malaga (Spain),
Skaraborg (Sweden). The details of participating institutions are
available on the EUBIROD website.16
Data collection
Partners were asked to complete a Word document and return it by
email to the Coordination Centre. Continuous legal advice was
provided to ensure correctness and completeness of answers and
avoid any potential misunderstanding in the interpretation of
questions. Various rounds of submissions/corrections were
undertaken to complete the process and allocate all answers
correctly.
Data from the questionnaire were recorded in an Excel spread-
sheet, saved in Comma-separated Value (csv) format and submitted
to the statistical routine for reporting.
Statistical analysis
Scores for privacy factors were derived by re-coding the original
values of each question (0: No, 1: Yes, 2: Not Applicable/Not
Determined, 9: Missing—Blank or Comment Only) to ‘1’ for a
positive, privacy protective conduct, and ‘0’ for a non-privacy
compliant procedure. The overall score for each factor (section)
was computed as the sum of re-coded values. Standardized factors
for each register were computed as a percentage of the factor score
on the total attainable overall score for each factor. The overall level
of privacy protection was computed as a composite indicator cor-
responding to the average of all standardized factors for each
participating register.
Statistical analysis included descriptive analysis of questions,
factors and overall scores with the associated 95% confidence
intervals (CIs). The median, range for overall factor scores were
computed to take into account the skewed distribution of
responses. A variety of graphs were produced to display results
from the questionnaire relative to single questions, factors, and the
overall questionnaire (histograms, boxplots, starplots and dotplots).
Ad hoc software written in the R statistical language19 was developed
specifically to produce all results.
IT platform
The IT platform includes an electronic version of the questionnaire
and a complete management system allowing new users to submit
their questionnaires, validated by the IT platform administrator. A
csv file is extracted and directly submitted to the R source code to
update the report and produce all graphical outputs. Results
delivered by the R program are then included in a user interface
through which each register can browse own results of privacy per-
formance against those obtained by others, whose identity is never
disclosed. The IT platform is directly available from the EUBIROD
website.16
Results
A total of 18 out of 19 EUBIROD registers returned the
questionnaire.
Table 1 presents the main summary results for all standardized
privacy factors.
Over 50% of the registers recorded a maximum score (100%) for
the following factors: accountability, openness, anonymization and
challenging compliance. Questions related to ‘collection of personal
information’ highlighted that 44% of the registers make secondary
use of registry data. Only 22% of the registers collect information
from public databases and 33% from multiple sources using a
common patient identifier. Consent to collect and process
personal data in the registry is required by 61% of the centres. In
the remaining cases, registers are built without patient consent by
authority of law, which also meets privacy requirements.
The factor ‘use of personal information’ highlighted that data
linkage is performed by 50% of the registers.
Median values showed that the most problematic privacy factors
are:
 disclosure and disposition (40%) and
 individual access (50%)
However, factors e.g. consent, use of personal information and
accuracy are also of concern, with a median of 75%.
A high variability of scores was found for the following factors
(standard deviation, range):
 challenging compliance (39%, 0–100%); anonymization (35%,
45–100%); openness (30%, 0–100%); consent (28%, 17–100%);
accuracy (26%, 17–100%) and individual access (25%, 0–100%).
Figures 1–3 summarize the results in a graphical format.
At the end of the study, each register was provided with a privacy
performance report deployed on the IT platform in de-identified
format. Privacy reports present average results in tabular and
graphical display, showing own median scores (overall and for
each factor) against those attained by the entire sample, along
with the relative 95% CI.
Table 1 Results of EUBIROD PIA for standardized factors and overall average as a percentage of the maximum attainable score
Factor Description No. Questions Mean (SD) 95% CI Median Range
A1 Accountability 3 96.3 (15.7) 89.0–100.0 100.0 33.0–100.0
A2 Collection 6 83.3 (15.1) 76.3–90.3 83.3 50.0–100.0
A3 Consent 6 71.3 (28.5) 58.1–84.4 75.0 16.7–100.0
A4 Use 4 73.6 (13.5) 67.4–79.8 75.0 25.0–100.0
A5 Disclosure 5 44.4 (11.0) 39.4–49.5 40.0 20.0–60.0
A6 Accuracy 6 69.4 (25.7) 57.6–81.3 75.0 16.7–100.0
A7 Safeguarding 8 80.6 (18.8) 71.9–89.2 81.2 37.5–100.0
A8 Openness 2 80.6 (30.3) 66.5–94.6 100.0 0.0–100.0
A9 Access 4 55.6 (25.1) 44.0–67.1 50.0 0.0–100.0
A10 Compliance 2 75.0 (39.3) 56.8–93.2 100.0 0.0–100.0
A11 Anonymization 3 79.6 (34.6) 63.7–73.5 100.0 44.5–100.0
OVERALL 73.6 (11.1) 68.5–78.8 74.8 68.5–78.8
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Discussion
The completeness of information available from disease registers is
paramount for making best use of data for research, monitoring,
surveillance, quality improvement and efficient planning of
healthcare systems. Understanding the nature and causes of
potential information loss may help avoiding wrong decisions
based on unreliable results (e.g. organizational changes following
clinical audits where high-risk groups have been systematically
excluded).
Sustainable strategies to rapidly improve data quality, e.g. policies
to reduce the variability of unexplained cultural barriers, can be
highly convenient, particularly in a time of financial pressure. Our
survey highlighted that database administrators of diabetes registers
normally do not have access to personal information stored in
routine databases and/or across multiple sources, perform data
linkage only in half of the cases and can hardly use data for
secondary purposes.
These findings may be due to structural limitations e.g. lack of a
personal identifier or scarce resources. However, registers involved
in EUBIROD are well established in countries where these
conditions are usually met.
On the other hand, these shortcomings provide an empirical
estimate of the potential effect of the heterogeneous implementation
A3
A2
A1A11A10
A9
A8
A7
A6 A5
A4
Figure 2 Privacy profiles of EUBIROD registers. Each starplot represents the profile of a single EUBIROD diabetes register. Rays represent the
level of each factor according to the legend located in the lower right corner. Registers are displayed anonymously (the order does not
correspond to the presentation order in the main text)
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11
0
20
40
60
80
10
0
Figure 1 Distribution of factor scores in the EUBIROD sample.
Boxplots represent the median, upper and lower quartiles, with
whiskers at 1.5 times the interquartile range, plus any outlying
values. Factors are coded A1–A11 according to the order they have
been presented in the methods section
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of the DPD across MS, one of the aspects at the basis of recent
developments in EU privacy legislation.12 As conflicts of interests
exist between the needs of privacy protection and those of public
health, targeted solutions should be implemented to achieve an
optimal balance between the two interests.
The 1995 DPD10 imposes specific conditions and limitations for
the legitimate processing of personal information (Articles 7 and 8),
unless data is to be considered anonymous.
The DPD strongly encourages the recognition and implementa-
tion of the right to privacy and data protection, but clearly
recognizes the need of societies to attain better healthcare by
providing several exemptions to the prohibition of processing
sensitive data when health improvements are involved; e.g. Article
8(3–4). Article 8(3) justifies the processing of health data, without
patients’ consent, for the purposes of preventive medicine, medical
diagnosis, the provision of care or treatment and the management of
healthcare services. Consent would be necessary to process the same
data for any secondary purpose; e.g. Article 8(4). MS can provide
additional exemptions to those laid down by the DPD for reasons of
substantial public interest. According to Recital 34 of the DPD,
public health is included in the notion of substantial public
interest. Nonetheless, only very few MS have translated this possi-
bility into national laws/regulations; while some others have adopted
specific exemptions only for selected activities.20 As a matter of fact,
MS who have not used the possibilities of Article 8(4), have made
data processing for public health purposes more difficult, differently
from what was originally envisaged by the EU legislator.
The implementation of the DPD at national level should be
carefully monitored to assess if, how and to what extent a
balanced approach has been achieved in practical national settings,
particularly in the field of public health. Therefore, it is crucial to
identify factors presenting the largest heterogeneity in the imple-
mentation of privacy principles and to highlight the key areas of
concern in privacy protection.
The EUBIROD PPA addressed these problems through a
quali-quantitative assessment of the level and variability of imple-
mentation of privacy norms/requirements across MS and the direct
identification of privacy principles that need targeted actions to be
fully complied with.
Furthermore, PPA includes an IT platform that allows
participating centres to identify their position in the distribution
of overall privacy results, and to identify the main areas of
concern by benchmarking scores for each factor against either
average values or specified targets.
The creation of a dedicated tool to improve the management of
privacy issues in diabetes registers may represent a practical solution
to feed privacy results back to individual centres and improve their
privacy performance. The PPA platform, preserving the identity of
registers, may favour the consolidation of collaborative models in a
sensitive area of legal inquiry. The PPA tool may also help improving
the quality of information required for the production of public
health indicators by targeting factors e.g. the ‘accuracy of personal
information’, where the observed low scores may relate to difficulties
in using additional sources and data for secondary purposes.
Scaled Score
0 20 40 60 80 100
TOTAL
Anonymisation
Compliance
Access
Openness
Safeguarding
Accuracy
Disclosure
Use
Consent
Collection
Figure 3 Privacy performance self-evaluation chart. A chart is produced for each EUBIROD centre to benchmark its level of adherence to
privacy principles against the general results. For each factor and overall, the register score (small diamond) is plotted against the average
(plus sign) and the computed 95% confidence limits (large diamonds). In this example, a register presents optimal levels of accountability,
safeguarding and compliance, but low levels for anonymization, access and exceedingly low levels of collection, consent, disclosure,
accuracy and openness. Overall, the centre is an outlying privacy under-performer
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To overcome this issue, both privacy protection and data accuracy
should be ensured by enforcing appropriate safeguards for data
processing operations posing privacy risks.21 In addition to the
novel solutions proposed in BIRO and EUBIROD, other means
could be safely used to improve data quality. For instance, data
linkage is a crucial area where solutions e.g. trusted third parties
could be implemented to guarantee the respect of privacy norms.
However, targeted survey instruments should be explored to test the
robustness of these solutions in detail.
Finally, some limitations of our study must be outlined.
The identification of privacy factors in the questionnaire was
internally performed by the EUBIROD Consortium. Nevertheless,
the direct reference of each question to EU and international legis-
lation/guidelines is fairly evident and transparently reflected in our
results.
Results are based on a sample of diabetes registers. However, the
study includes a large number of countries, whose centres are all
highly regarded internationally in a field e.g. diabetes, which
involves managing large databases and using highly standardized
electronic health records.
The scoring system applied for analysing privacy factors is based
on a simple linear sum of the individual questions. The overall level
of privacy protection assumes that all factors weigh equally. These
assumptions should be properly tested in a targeted study.
Conclusions
The model of PPA developed in EUBIROD proposes a new method
that allows measuring the level of implementation of privacy
principles/norms as well as identifying the key areas of concern
that require targeted actions at both the national and European
level. At the level of disease registers, it makes possible to identify
key areas of concern, including those influencing data quality, and
apply appropriate corrective measures. At EU level, it allows
performing a sound assessment of the variability in the implemen-
tation of the DPD across MS, highlighting privacy principles/factors
that need to be strengthened.
The overall model is designed to foster the uptake of privacy/data
protection principles and generate local quality improvement loops
that would result into more solid transnational information
exchange for public health.
A concerted action at both the legislative level and point of care
provision is overtly needed to achieve the right balance between
privacy/data protection and better health.
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Key points
 Diabetes registers from 18 countries normally do not have
access to personal information from routine databases and/
or multiple sources; they perform data linkage only in half of
the cases and rarely use data for secondary purposes.
 The ‘Privacy Performance Assessment’ platform supports
privacy protection and quality improvement on a routine
basis.
 The overall model of the ‘Privacy Performance Assessment’
may favour the homogeneous implementation of the DPD,
while enabling more solid transnational exchange of public
health information.
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Background: Delays in the diagnosis of tuberculosis reflect a lack of access to care, and contribute to ongoing
tuberculosis transmission in the community. The objective of this study was to evaluate the delay in tuberculosis
testing and the associated risk factors in Shanghai, Shandong and Sichuan provinces in China. Methods: A pro-
spective cohort study of 765 culture-positive pulmonary tuberculosis patients registered between December 2006
and December 2008. The delay between the onset of symptoms and tuberculosis diagnosis testing and patient
information were recorded in a questionnaire and analysed. Results: The median delay was 36 days and was
significantly shorter in patients from Shanghai compared with other places (30 vs. 42 days, P<0.001). Multivariate
analysis revealed that cough in Shanghai patients, lowest income level, being married and presenting expector-
ation in Shandong and Sichuan patients, were associated with a delay in the diagnosis testing of tuberculosis of
>30 days. The only factor associated with a delay of >90 days was, in Shandong and Sichuan provinces only, female
gender. The presence of other pulmonary symptoms like haemoptysis and loss of weight, fever and chills could
shorten these delays. Conclusion: Efforts to shorten delays in the diagnosis of tuberculosis must target vulnerable
populations. The non-specific symptom of cough is a risk factor associated with longer delays. Training for
healthcare workers in areas with a high incidence of tuberculosis, where a delayed diagnosis in coughers may
enhance tuberculosis transmission in the community, is of paramount importance.
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Introduction
Tuberculosis (TB) is a major global health burden with more than9 million people developing the active disease annually. The
World Health Organization’s (WHO) global targets for reducing
the burden of disease attributed to TB are to halt and to begin to
reverse the high incidence of TB. To meet these targets, the
proportion of new TB cases detected should be 84% of all infected
cases globally by 2015.1 Between 2000 and 2005, the case detection
rate for new smear-positive cases in China increased from 31 to 73%
but remained stable in 2008.1
TB control can be effectively achieved if individuals with the
disease are diagnosed in a timely manner and receive adequate
and timely treatment. A delay in diagnosis reflects a lack of access
to TB care that delays treatment for the individual patient, as well as
increasing the risk of TB transmission in the community until the
patient is treated.2,3 In most Chinese studies, low-income, female
and rural TB patients are at a high risk of receiving a late
diagnosis.4–9
In China, beginning in the early 1990s, huge efforts and re-
sources have been aimed at strategies involving short courses of
directly observed treatments (DOTs) that emphasize passive
case-finding that would otherwise result in delayed diagnoses.
The incidence rate of TB decreased from 113/100 000 in 2003 to
96/100 000 in 2009 with an estimated 1.3 million new cases
and 160 000 deaths attributable to TB in 2009.1,10 In our study
areas, patients may go to any general hospital, community health
centre or countryside health care facility. If the patient has TB
symptoms such as cough for 2 weeks, weight loss or fever, a
chest X-ray will be done for screening. Patients suspected of
having TB are referred to a TB hospital for definitive diagnosis
and free treatment.
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